Trials / Not Yet Recruiting
Not Yet RecruitingNCT07265206
A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
An Exploratory Clinical Study on the Safety and Efficacy of HY001N Cell Injection in the Treatment of Relapsed or Refractory Autoimmune Neurological Diseases
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Juventas Cell Therapy Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of HY001N cell injection in the treatment of patients with relapsed/refractory Neurological Autoimmune Diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HY001N cell injection | A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, HY001N. |
Timeline
- Start date
- 2025-12-30
- Primary completion
- 2026-12-30
- Completion
- 2028-12-30
- First posted
- 2025-12-04
- Last updated
- 2025-12-04
Source: ClinicalTrials.gov record NCT07265206. Inclusion in this directory is not an endorsement.